Xarelto plaintiffs are asking that federal lawsuits be consolidated in East St. Louis, IL. Bloomberg reports that there are approximately 50 cases filed in 15 different federal courts to date. The plaintiffs have requested that a multidistrict litigation be formed to help move the cases along more efficiently.
Xarelto is a blood thinner that was first approved for use in 2011. The medication is intended to prevent blood clots in patients undergoing ...
continue reading...Lawsuits are being filed over the use of the blood-thinning drug Xarelto and, although it is early in the litigation, lawyers believe there may be a substantial number of cases filed in the future. Some Xarelto lawyers are looking to create a Philadelphia mass tort program for the Xarelto lawsuits as the numbers of cases continues to grow. A recent story in The Legal Intelligencer notes that cases are being filed against a Johnson & ...
Bayer AG, a large German pharmaceutical company, is facing its first lawsuits in the United States over its anti-clotting drug Xarelto. A June 14 article reported that there are fewer than 10 Xarelto lawsuits currently filed.
In July 2011, the FDA approved Xarelto to prevent deep vein thrombosis in patients having knee or hip replacement surgery. In November 2012, the drug was approved to prevent pulmonary embolisms. In ...
continue reading...
A U.S. Food and Drug Administration advisory panel has voted against approving Johnson & Johnson’s blood thinner Xarelto for prevention of blood clots in people with acute coronary syndrome.
According to U.S. News and World Report, the 6-to-4 decision came as a surprise because an FDA briefing document filed Monday in advance of the ruling gave the drug a favorable assessment.
But panel members reportedly said company studies did not provide enough ...
continue reading...
According to a story in the Washington Post, Johnson & Johnson has applied to the U.S. Food and Drug Administration to get approval of another use for its anti-clotting drug Xarelto.
Johnson & Johnson currently markets Xarelto for reducing the risk of blood clots in patients after knee or hip replacement surgery, and reducing the risk of stroke and other blood clots in people with a type of irregular heartbeat. The ...
continue reading...German corporation Bayer has announced that its four most promising drugs, led by newly-launched anti-clotting pill Xarelto, may account for combined annual sales of as much as $6.5 billion, according to a Reuters report.
The report says Bayer’s healthcare division is aiming for sales of roughly $26.2 billion in 2014, up from $22.4 billion last year.
The company said prescription drug sales were set to rise to about $15 billion by 2014, up 16 percent from 2011, fueled largely by new product ...
continue reading...
